US 12,145,939 B2
Substituted [1,2,4]triazolo[4,3-a]pyrazines as ion channel modulators
Kiran Reddy, Boston, MA (US); Gabriel Martinez Botella, Wayland, MA (US); Andrew Mark Griffin, Montreal (CA); Brian Edward Marron, Ada, MI (US); and Carlos Loya, Cambridge, MA (US)
Assigned to Praxis Precision Medicines, Inc., Boston, MA (US)
Filed by PRAXIS PRECISION MEDICINES, INC., Boston, MA (US)
Filed on Aug. 4, 2023, as Appl. No. 18/365,695.
Application 18/365,695 is a division of application No. 17/104,512, filed on Nov. 25, 2020, granted, now 11,767,325.
Claims priority of provisional application 62/940,489, filed on Nov. 26, 2019.
Claims priority of provisional application 62/940,502, filed on Nov. 26, 2019.
Claims priority of provisional application 62/940,503, filed on Nov. 26, 2019.
Prior Publication US 2024/0043433 A1, Feb. 8, 2024
Int. Cl. A61K 31/4985 (2006.01); A61P 25/00 (2006.01); C07D 487/04 (2006.01)
CPC C07D 487/04 (2013.01) [A61P 25/00 (2018.01)] 19 Claims
 
1. A compound of Formula (III-II):

OG Complex Work Unit Chemistry
or a pharmaceutically acceptable salt or stereoisomer thereof,
wherein:
R5 is halo, C1-4 alkyl, or C3-6 cycloalkyl, wherein the C1-4 alkyl is optionally substituted with one OC1-4 alkyl or OC3-6 cycloalkyl substituent;
R6 is C1-4 alkyl or C1-4 haloalkyl, wherein the C1-4 alkyl or C1-4 haloalkyl is substituted with one ORc substituent;
R7 is a monocyclic C3-6 cycloalkyl, wherein the C3-6 cycloalkyl is substituted with one or more independently selected Ra substituents;
each Ra is independently halo, C1-4 alkyl, C1-4 haloalkyl, OC1-4 alkyl, or OC1-4 haloalkyl;
Rc is C1-4 alkyl or C3-6 cycloalkyl, wherein the C1-4 alkyl is optionally substituted with one C3-6 cycloalkyl or phenyl substituent; and
m is 0, 1, or 2.